Core Insights - Tempus AI, Inc. has achieved significant milestones, including a Total Contract Value exceeding $1.1 billion and data agreements with over 70 pharmaceutical customers [1][9] - The company reported positive adjusted EBITDA of $1.5 million in Q3 2025, marking a year-over-year improvement of $23.3 million [2][9] - Tempus has participated in nearly 1,500 research projects over the past decade, leveraging its AI-powered platform to support both clinical and therapeutic research [3][9] Company Performance - Tempus' shares have increased by 39.8% over the past year, significantly outperforming the industry, which saw a decline of 7.8% [8] - The S&P 500 composite index improved by 17.2% during the same period [8] Financial Metrics - Tempus currently trades at a forward Price-to-Sales (P/S) ratio of 7.93, compared to the industry average of 5.77 [10] - The loss per share estimate for 2025 has remained unchanged over the past 30 days, with estimates at -0.64 [11][12]